AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company. The company AUMED Immunology a.s. was founded with the aim of registering and marketing a new medicinal product containing transfer factor as an active medicinal substance in the form of an oral lyophilized tablet. The new medicinal product will be based on the results of own research activities in the field of transfer factors (more detailed information here). The registration plan for a newly developed medicinal product belongs to the long-term business concept and strategy of AUMED, a.s.. You can learn more about the registration process and clinical trials on AUMED Immunology’s own website. (www.aumedimmunology.cz).
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
You can adjust all of your cookie settings by navigating the tabs on the left hand side.